Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

This biotech has candidates in late-stage clinical development.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

The sector looks overvalued, and retail investors have pumped prices higher.